Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBM Cambrex	$59.99	$59.99	$33.80 ▼ $60.29	$2.02B	2.14	218,726 shs	N/A
EIDX Eidos Therapeutics	$122.21	$123.21	$28.39 ▼ $132.54	$4.75B	-0.16	128,113 shs	N/A
FTSV Forty Seven	$95.51	$95.51	$5.53 ▼ $95.51	$4.60B	0.4	1.61 million shs	N/A
HRTX Heron Therapeutics	$1.93 -3.5%	$2.02	$1.04 ▼ $3.40	$305.13M	1.18	2.14 million shs	1.06 million shs
XNCR Xencor	$8.97 -1.1%	$8.50	$7.16 ▼ $27.24	$645.52M	0.85	685,677 shs	417,365 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBM Cambrex	0.00%	0.00%	0.00%	0.00%	0.00%
EIDX Eidos Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
FTSV Forty Seven	0.00%	0.00%	0.00%	0.00%	0.00%
HRTX Heron Therapeutics	-0.99%	-9.91%	+2.56%	+8.70%	-42.86%
XNCR Xencor	+2.72%	-2.26%	+9.15%	-6.49%	-54.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CBM Cambrex	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EIDX Eidos Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FTSV Forty Seven	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	3.5659 of 5 stars	3.5	0.0	0.0	4.2	1.7	1.7	0.6
XNCR Xencor	4.3692 of 5 stars	3.4	5.0	0.0	3.9	1.7	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CBM Cambrex	0.00	N/A	N/A	N/A
EIDX Eidos Therapeutics	0.00	N/A	N/A	N/A
FTSV Forty Seven	0.00	N/A	N/A	N/A
HRTX Heron Therapeutics	3.00	Buy	$5.00	159.07% Upside
XNCR Xencor	2.75	Moderate Buy	$28.00	212.15% Upside

Current Analyst Ratings Breakdown

Latest FTSV, CBM, HRTX, EIDX, and XNCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/8/2025	XNCR Xencor	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$22.00 ➝ $6.00
4/30/2025	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$31.00
4/21/2025	XNCR Xencor	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CBM Cambrex	$532.09M	3.80	$3.91 per share	15.36	$19.48 per share	3.08
EIDX Eidos Therapeutics	$26.69M	177.99	N/A	N/A	$4.57 per share	26.74
FTSV Forty Seven	$15.68M	293.33	N/A	N/A	$7.52 per share	12.70
HRTX Heron Therapeutics	$144.29M	2.04	N/A	N/A	($0.22) per share	-8.77
XNCR Xencor	$110.49M	5.78	N/A	N/A	$9.63 per share	0.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CBM Cambrex	$92.41M	$2.77	21.66	∞	N/A	5.96%	5.38%	2.50%	N/A
EIDX Eidos Therapeutics	-$37.83M	-$1.03	N/A	N/A	N/A	N/A	-65.21%	-53.04%	N/A
FTSV Forty Seven	-$87.62M	-$2.34	N/A	N/A	N/A	N/A	-50.38%	-44.35%	N/A
HRTX Heron Therapeutics	-$13.58M	-$0.06	N/A	N/A	N/A	-5.24%	N/A	-3.43%	8/5/2025 (Estimated)
XNCR Xencor	-$232.62M	-$3.06	0.00	N/A	N/A	-181.17%	-31.94%	-22.19%	8/4/2025 (Estimated)

Latest FTSV, CBM, HRTX, EIDX, and XNCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	HRTX Heron Therapeutics	-$0.01	N/A	N/A	N/A	$38.08 million	N/A
8/4/2025	Q2 2025	XNCR Xencor	-$0.78	N/A	N/A	N/A	$22.59 million	N/A
5/8/2025	Q1 2025	XNCR Xencor	-$0.60	-$0.66	-$0.06	-$0.66	$23.44 million	$32.73 million
5/6/2025	Q1 2025	HRTX Heron Therapeutics	-$0.01	$0.01	+$0.02	$0.01	$37.08 million	$38.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CBM Cambrex	N/A	N/A	N/A	N/A	N/A
EIDX Eidos Therapeutics	N/A	N/A	N/A	N/A	N/A
FTSV Forty Seven	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CBM Cambrex	0.76	2.37	1.70
EIDX Eidos Therapeutics	0.14	11.10	11.10
FTSV Forty Seven	N/A	14.81	14.81
HRTX Heron Therapeutics	N/A	2.40	1.76
XNCR Xencor	0.16	5.89	5.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CBM Cambrex	90.96%
EIDX Eidos Therapeutics	31.40%
FTSV Forty Seven	71.77%
HRTX Heron Therapeutics	80.01%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
CBM Cambrex	1.41%
EIDX Eidos Therapeutics	70.10%
FTSV Forty Seven	37.40%
HRTX Heron Therapeutics	5.86%
XNCR Xencor	4.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CBM Cambrex	1,732	33.72 million	N/A	Optionable
EIDX Eidos Therapeutics	70	38.87 million	N/A	Not Optionable
FTSV Forty Seven	57	48.16 million	N/A	Not Optionable
HRTX Heron Therapeutics	300	152.56 million	143.62 million	Optionable
XNCR Xencor	280	71.17 million	67.78 million	Optionable

FTSV, CBM, HRTX, EIDX, and XNCR Headlines

Recent News About These Companies

Xencor (NASDAQ:XNCR) Stock Price Down 4.3% - What's Next?

July 11, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Shares Pass Above 50 Day Moving Average - What's Next?

July 11, 2025 | marketbeat.com

Xencor (NASDAQ:XNCR) Trading 7.3% Higher - What's Next?

July 9, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of "Moderate Buy" by Analysts

July 3, 2025 | marketbeat.com

Xencor, Inc. (XNCR) Latest Stock News & Headlines - Yahoo Finance

June 29, 2025 | ca.finance.yahoo.com

Insider Selling: Xencor, Inc. (NASDAQ:XNCR) Director Sells 2,215 Shares of Stock

June 17, 2025 | insidertrades.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA)

May 13, 2025 | theglobeandmail.com

Xencor Reports First Quarter 2025 Financial Results

May 7, 2025 | uk.finance.yahoo.com

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

May 7, 2025 | zacks.com

Xencor, Inc. (NASDAQ:XNCR) EVP Nancy Valente Sells 4,616 Shares

May 7, 2025 | insidertrades.com

Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know

May 1, 2025 | zacks.com

William Blair starts Xencor stock with Outperform rating

April 23, 2025 | uk.investing.com

William Blair Initiates Coverage of Xencor (XNCR) with Outperform Recommendation

April 22, 2025 | msn.com

Xencor initiated with an Outperform at William Blair

April 21, 2025 | markets.businessinsider.com

Xencor participates in a conference call with JPMorgan

April 18, 2025 | markets.businessinsider.com

Xencor, Inc.: No Major Near Term Catalysts

April 11, 2025 | seekingalpha.com

Xencor (XNCR) Upgraded to Buy: Here's Why

April 10, 2025 | zacks.com

Xencor’s SWOT analysis: biotech stock faces pivotal year ahead

April 10, 2025 | uk.investing.com

Barclays Keeps Their Sell Rating on Xencor (XNCR)

April 3, 2025 | markets.businessinsider.com

The Court of Appeals for the Federal Circuit’s In Re Xencor Decision: Jepson Claims Require Written Description for Their Preambles

March 24, 2025 | jdsupra.com

Latest Federal Court Cases: In re: Xencor, Inc.

March 18, 2025 | jdsupra.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTSV, CBM, HRTX, EIDX, and XNCR Company Descriptions

Cambrex NYSE:CBM

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

Eidos Therapeutics NASDAQ:EIDX

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.

Forty Seven NASDAQ:FTSV

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Heron Therapeutics NASDAQ:HRTX

$1.93 -0.07 (-3.50%)

Closing price 04:00 PM Eastern

Extended Trading

$1.94 +0.01 (+0.52%)

As of 07:55 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Xencor NASDAQ:XNCR

$8.97 -0.10 (-1.10%)

Closing price 04:00 PM Eastern

Extended Trading

$8.97 0.00 (0.00%)

As of 04:33 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time